FY2020 Earnings Estimate for CRH Medical Corp (CRHM) Issued By Clarus Securities

CRH Medical Corp (NYSEAMERICAN:CRHM) – Investment analysts at Clarus Securities decreased their FY2020 earnings per share estimates for shares of CRH Medical in a research report issued on Wednesday, March 20th, according to Zacks Investment Research. Clarus Securities analyst N. Atkinson now forecasts that the company will post earnings per share of $0.07 for the year, down from their previous forecast of $0.12. Clarus Securities currently has a “Buy” rating on the stock.

A number of other equities analysts have also recently commented on CRHM. Zacks Investment Research raised shares of CRH Medical from a “sell” rating to a “hold” rating in a research note on Thursday, December 27th. TD Securities reiterated a “buy” rating on shares of CRH Medical in a report on Tuesday, January 8th. Finally, TheStreet lowered shares of CRH Medical from a “b-” rating to a “c+” rating in a report on Friday, March 29th.

Shares of CRHM stock traded up $0.01 during trading hours on Friday, reaching $2.82. 78,500 shares of the stock were exchanged, compared to its average volume of 76,490. CRH Medical has a 12-month low of $2.51 and a 12-month high of $4.50.

CRH Medical (NYSEAMERICAN:CRHM) last issued its quarterly earnings data on Wednesday, March 13th. The company reported $0.02 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.02. The company had revenue of $32.02 million for the quarter, compared to the consensus estimate of $31.40 million.

Large investors have recently bought and sold shares of the company. Nantahala Capital Management LLC grew its position in shares of CRH Medical by 6.1% in the 4th quarter. Nantahala Capital Management LLC now owns 6,534,155 shares of the company’s stock worth $20,028,000 after buying an additional 378,329 shares during the last quarter. Two Sigma Advisers LP boosted its holdings in shares of CRH Medical by 12.6% in the 4th quarter. Two Sigma Advisers LP now owns 220,300 shares of the company’s stock valued at $675,000 after acquiring an additional 24,700 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of CRH Medical by 21.7% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 2,201,799 shares of the company’s stock valued at $6,739,000 after acquiring an additional 392,900 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of CRH Medical by 163.9% in the 4th quarter. Acadian Asset Management LLC now owns 234,320 shares of the company’s stock valued at $716,000 after acquiring an additional 145,520 shares during the last quarter. Finally, Beutel Goodman & Co Ltd. boosted its holdings in shares of CRH Medical by 3.5% in the 4th quarter. Beutel Goodman & Co Ltd. now owns 5,127,100 shares of the company’s stock valued at $1,570,000 after acquiring an additional 171,970 shares during the last quarter.

About CRH Medical

CRH Medical Corporation provides various products and services to gastroenterologists in the United States and Canada. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid. The company also offers anesthesia services for patients undergoing endoscopic procedures.

Featured Article: Investing strategies using the yield curve

Get a free copy of the Zacks research report on CRH Medical (CRHM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CRH Medical (NYSEAMERICAN:CRHM)

Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.